In-use testing of extemporaneously prepared suspensions of second generation non-nucleoside reversed transcriptase inhibitors in support of phase I clinical studies.
DPC 961 and 963 are two of a series of prospective second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) being considered for the treatment of HIV infections. The 'powder in a bottle' approach was used for drug administration for Phase I clinical studies. This new approach consists of compounding the active drug as a suspension or solution at the clinical site immediately before dosing. Prior to clinical use, studies were conducted to determine the compatibility of the drugs with the suspending agent, the recovery of the drugs using the administration procedure and the dissolution profile of the suspensions. The stability of the DPC 961 and 963 in the dosing formulation was followed over a 24-h period using a stability indicating HPLC method. In addition, the dissolution profiles of the suspensions were established for future comparison with solid dosage forms. Although the two drugs have very similar chemical structures, they clearly exhibited different behaviors in liquid/liquid extraction and dissolution experiments. These differences could be related to the physical characteristics of the powders, such as particle size and surface area. The results of the in-use testing of the suspension showed adequate recovery of the drugs from the bottle at two drug levels. The stability of DPC 961 and 963 in the suspending agent was sufficient for constitution and administration of the suspensions at the clinical site.
Aubry
A F
AF
Pharmaceutical Research and Development Experimental Station, DuPont Pharmaceuticals Company, Wilmington, DE 19880-0353, USA.
Sebastian
D
D
Hobson
T
T
Xu
J Q
JQ
Rabel
S
S
Xie
M
M
Gray
V
V
D019380:Anti-HIV Agents / Q000737:chemistry; D002851:Chromatography, High Pressure Liquid; D017321:Clinical Trials, Phase I as Topic; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D011799:Quinazolines / Q000737:chemistry*; D052999:Quinazolinones; D015363:Quinolones / Q000737:chemistry*; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry*; D012995:Solubility; D013056:Spectrophotometry, Ultraviolet
D019380:Anti-HIV Agents; C413505:DPC 961; C415683:DPC 963; D004364:Pharmaceutical Preparations; D011799:Quinazolines; D052999:Quinazolinones; D015363:Quinolones; D018894:Reverse Transcriptase Inhibitors